Disease	Advanced cancer/solid tumor only
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	No designated number of regimens
Type of Study – 1	Phase I
Type of Study – 2	Dose evaluation
Primary Endpoint	Safety
Primary Endpoint	Tolerability
Secondary Endpoint	Clinical benefit per objective response or progression‐free survival (RECIST version 1.1)
Additional Details of Endpoints or Study Design	Exploratory endpoint: immune analysis
Investigator's Analysis	Drug tolerable, some efficacy observed in chordoma